IL-2 Program Profits with Bonum's Drs. John Mulligan and Neela Patel

On this week"s episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum"s transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche. The asset, a PD-1-regulated IL-2 program, was a product of a platform that the new Bonum retains, and its sale to Roche was orchestrated by Dr. Patel. You"ve seen the terms of the deal in the news, but on this episode, you"ll get the inside scoop on how the deal was done, how it set Bonum up for future paltform-driven succes, and how these two leaders retained its IP and its people through a fast, unique, and disruptive acquisition.  Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It"s a once-per-month dose of insight and intel that you"ll actually look forward to receiving! Check it out at bioprocessonline.com/bob!